timothy sykes logo
CareDx CDNA Soars After Big Earnings Beat And Guidance Hike Thumbnail
G Google News

CareDx CDNA Soars After Big Earnings Beat And Guidance Hike

TIM SYKES•UPDATED OCT. 30, 2026, 12:33 PM ET
Reviewed by Bryce Tuoheyand Fact-checked by Matt Monaco

CareDx Inc. shares surged as pivotal transplant-testing news drove renewed investor confidence; stocks have been trading up by 23.03 percent.

Key Takeaways

  • Q3 revenue near $139M–$139.4M crushed roughly $122M consensus, with GAAP EPS jumping to $0.35 and adjusted EPS hitting $0.70.
  • Full-year 2026 revenue guidance lifted to $520M–$530M and EBITDA to $90M–$100M, both well above prior outlook and Street expectations.
  • Analysts at Canaccord and BTIG raised CDNA price targets to $80 and $81, reiterating Buy ratings on strong fundamentals and growth.
  • New kidney transplant data show AlloSure tests cut biopsies while keeping strong rejection prediction, even under tougher Banff 2024 criteria.

Candlestick Chart

Live Update At 12:32:35 EDT: On Friday, October 30, 2026 CareDx Inc. stock [NASDAQ: CDNA] is trending up by 23.03%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

CDNA just delivered the kind of quarter that forces traders back to their charts. CareDx posted Q3 revenue of about $139M–$139.4M, well ahead of the roughly $122M Wall Street was looking for. GAAP EPS jumped to $0.35 from $0.03 a year earlier, while adjusted EPS came in at $0.70, signaling serious operating leverage finally kicking in.

On the tape, that strength shows up as a clean breakout. CDNA closed at $69.85 on 2026/10/05 and has since pushed to $87.99 on 2026/10/30, a strong uptrend with higher lows from the low-$60s. The latest daily candle shows a gap from the low $80s to a high near $90, holding most of the move into the close — classic momentum after an earnings beat.

More Breaking News

Intraday, CDNA has been grinding in a tight $87–$89 range after the initial spike, with repeated dips getting bought around the mid-$87s. That tells active traders there is demand on every pullback. Add in fat gross margins around 70.6% and solid balance sheet ratios — low debt, high current ratio — and the fundamentals are now lining up with the price action.

Why Traders Are Watching CDNA Right Now

CDNA is suddenly acting like a leader, not a forgotten small-cap. The Q3 print changed the tone. CareDx’s $139M-plus revenue not only smashed consensus, it was driven by multiple engines: the core Transplant business, Specialty Oncology scaling up, and progress in cell therapy and molecular information. For traders, that diversification matters. The story is no longer a one-product bet.

The real catalyst, though, is the forward look. Management raised 2026 revenue guidance to $520M–$530M, versus prior $490M–$500M and Street expectations near $495M. At the same time, they boosted adjusted EBITDA guidance to $90M–$100M from $66M–$78M. When a name like CDNA guides both sales and earnings power higher in the same breath, models get rewritten and funds re-rate the stock.

Wall Street is already reacting. Canaccord took its CDNA price target up to $80 from $65, while BTIG stepped up to $81 from $74, both with Buy ratings and comments about underappreciated value and strong fundamentals. That type of alignment between the tape, the numbers, and the analyst community is exactly what momentum traders look for.

Underneath the financials, the clinical story is tightening. At ASN Kidney Week 2026, CareDx showed that AlloSure Kidney and AlloSure Plus can cut invasive biopsies while still predicting rejection risk, even under the updated Banff 2024 criteria. For CDNA, that is real-world validation that can support transplant test adoption and pricing power, giving traders more confidence that the revenue ramp has fuel.

Conclusion

For active traders, CDNA has moved from “watchlist maybe” to “must-watch” after this earnings cycle. The combination of a $139M-plus Q3 beat, raised 2026 revenue guidance to $520M–$530M, and a stronger EBITDA outlook tells a clear story: CareDx is growing faster and getting more profitable than the market expected. The multi-week price trend from the low $60s to the high $80s simply reflects that shift.

CDNA’s fundamentals now have firmer backing. High gross margins, low leverage, and free cash flow positive operations give CareDx room to keep funding R&D and commercial growth. The new AlloSure transplant data from ASN Kidney Week adds another layer, suggesting the company’s core transplant products are not just differentiated but also de-risked by large, multinational evidence.

Analyst upgrades from Canaccord and BTIG validate what the chart is already saying — the Street is re-rating the CDNA story higher. For traders, this is exactly the kind of setup Tim Sykes and Tim Bohen talk about: a catalyst-backed runner where “the news, the chart, and the volume all line up — that’s when you strike, but you still cut losses fast.” As millionaire penny stock trader and teacher Tim Sykes, says, “Preparation plus patience leads to big profits.” — and CDNA’s evolving story rewards exactly that kind of disciplined trading mindset.

This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”